Panbela Therapeutics, Inc.
- Tickers
- None listed
- Headquarters
- Not recorded
- SEC CIK
- 0001029125
- Website
- Not recorded
Closing prices
This company has no stock ticker on record, so there are no prices to show.
Drugs
| Drug | Indications | Phase | Next catalyst | CT-VCA | Trials |
|---|---|---|---|---|---|
| SBP-101 | Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV; Pancreatic Ductal Adenocarcinoma | Phase 2/3 | None scheduled | 1 |
FDA-approved applications
No Drugs@FDA application has a sponsor name that matches this company.
Data provided by the U.S. Food and Drug Administration (Drugs@FDA). Sponsors are matched to companies by name; subsidiaries do not link.
Catalysts
No catalysts yet. Editors add each date together with its source.
Deals
No approved deals involve this company yet.
Reported fundamentals (SEC XBRL)
| Metric | Reported value | Period | Filing |
|---|---|---|---|
| Revenue | 291,258 USD | 1 Apr 2015 to 30 Jun 2015 FY2015 Q2 | 10-Q for Revenue on sec.gov (opens in a new tab)Filed |
| Net income (loss) | −7,172,000 USD | 1 Jul 2024 to 30 Sep 2024 FY2024 Q3 | 10-Q for Net income (loss) on sec.gov (opens in a new tab)Filed |
| Research and development expense | 6,052,000 USD | 1 Jul 2024 to 30 Sep 2024 FY2024 Q3 | 10-Q for Research and development expense on sec.gov (opens in a new tab)Filed |
| Operating expenses | Not reported in XBRL filings since 2015 | ||
| Cash and cash equivalents | 142,000 USD | At 30 Sep 2024 FY2024 Q3 | 10-Q for Cash and cash equivalents on sec.gov (opens in a new tab)Filed |
| Short-term investments and marketable securities | Not reported in XBRL filings since 2015 | ||
| Total liabilities | 23,336,000 USD | At 30 Sep 2024 FY2024 Q3 | 10-Q for Total liabilities on sec.gov (opens in a new tab)Filed |
| Stockholders' equity | −18,168,000 USD | At 30 Sep 2024 FY2024 Q3 | 10-Q for Stockholders' equity on sec.gov (opens in a new tab)Filed |
| Common shares outstanding (cover page) | 4,854,831 shares | At 11 Nov 2024 FY2024 Q3 | 10-Q for Common shares outstanding (cover page) on sec.gov (opens in a new tab)Filed |
History
| Period | Reported value | Filing |
|---|---|---|
| 1 Apr 2015 to 30 Jun 2015 FY2015 Q2 | 291,258 USD | 10-Q filed 13 Aug 2015 on sec.gov (opens in a new tab)Filed |
| 1 Jan 2015 to 31 Mar 2015 FY2015 Q1 | 287,257 USD | 10-Q filed 15 May 2015 on sec.gov (opens in a new tab)Filed |
Values as reported in the company's XBRL filings to the SEC, one per calendar period (SEC frames); not adjusted, not audited by HealthTrade, and not investment advice.
Source: SEC XBRL company facts (opens in a new tab) · Licence: public-domain · as of 2026-10-25 · read
SEC filings
Source: SEC EDGAR. Each row links to the filing on sec.gov.
Related news
No recent headlines mention this company.
Insider transactions
All rows for Panbela Therapeutics, Inc. on Insider TradesLast 90 days of Form 4 filings, from 4 Aug 2026 (US Eastern dates).
- Buys code P
- None in this period
- Sells code S
- None in this period
- Other all other codes
- None in this period
Last transaction:
Insider filings are public records and are not a recommendation. Source: SEC EDGAR.
Sources
- Editor source (opens in a new tab) Licence: editorial. Entered by an editor, not fetched automatically
- SEC EDGAR submissions (opens in a new tab) Licence: public-domain. Fetched
Nothing on this page is investment advice.